<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02758509</url>
  </required_header>
  <id_info>
    <org_study_id>PROGRESSIVE-C</org_study_id>
    <nct_id>NCT02758509</nct_id>
  </id_info>
  <brief_title>Impact of Antiviral Therapy on Gastroesophageal Varices.</brief_title>
  <official_title>Efficacy and Safety of Interferon Based Therapy and Interferon-free Direct-acting Antivirals in Cirrhotic Patients With Hepatitis C. Impact of Antiviral Therapy on Gastroesophageal Varices.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parc de Salut Mar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Parc de Salut Mar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis C virus (HCV) chronic infection affects 200 million people worldwide. HCV antiviral
      treatment has evolved rapidly since 2011. The use of pegylated interferon (PEG-INF) with
      ribavirin (RBV) has supposed high serious adverse events (SAEs) and low efficacy, especially
      in patients with cirrhosis. The introduction of 1st generation protease inhibitors (PIs) in
      genotype-1 (GT1) HCV, such as boceprevir (BOC) and telaprevir (TVR), improved the efficacy
      but increased the SAEs. Currently, interferon-free direct-acting antivirals (IF-DAAs) achieve
      great effectiveness with minimum SAEs. However, studies evaluating efficacy and safety of
      DAAs in cirrhotic patients are limited in real clinical practice. The aim of our study is to
      evaluate in HCV-cirrhotic patients the efficacy and safety of 3 treatment strategies
      (PEG-IFN/RBV, PEG-IFN/RBV/PIs, and IF-DAAs) in routine practice according to European
      guidelines from 2010 to 2015. The secondary aim is to evaluate the impact of sustained
      virological response on gastroesophageal varices (GOV).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 1, 2010</start_date>
  <completion_date type="Actual">October 15, 2017</completion_date>
  <primary_completion_date type="Actual">June 15, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>sustained virological response (SVR)</measure>
    <time_frame>12 weeks after treatment completion</time_frame>
    <description>undetectable HCV viral load 12 weeks after the end of antiviral treatment in each cohort of antiviral treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with gastroesophageal varices</measure>
    <time_frame>gastroesophageal varices (GOV) before antiviral treatment and 12-24 weeks after treatment completion</time_frame>
    <description>Number of patients with GOV before and 12-24 weeks after treatment completion in patients with or without SVR</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">237</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>PEG/RBV</arm_group_label>
    <description>Pegylated interferon alfa-2a 180 microg/week plus ribavirin 800-1200 mg during 48 weeks according to routine practice and European Guidelines (EASL recommendations 2011)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG/RBV+BOC or TVR</arm_group_label>
    <description>Boceprevir 800 mg/8h or Telaprevir 750 mg/8h plus Pegylated interferon alfa-2a 180 microg/week plus ribavirin 800-1200 mg during 48 weeks according to routine practice and European Guidelines (EASL recommendations 2014)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IF-DAAs</arm_group_label>
    <description>Interferon-free direct-acting antiviral combinations according to routine practice and European Guidelines (EASL recommendations 2015)
Fixed-dose combination of sofosbuvir (400 mg) and ledipasvir (90 mg) daily +/- ribavirin 12-24 weeks
Fixed-dose combination of ombitasvir (75 mg), paritaprevir (12.5 mg) and ritonavir (50 mg) in one single tablet (two tablets once daily) and dasabuvir (250 mg) (one tablet twice daily) with ribavirin 800-1200 mg 12 weeks (Genotype 1b) or 24 weeks (genotype 1a)
Daily sofosbuvir (400 mg) and daily simeprevir (150 mg) +/- ribavirin 12-24 weeks
Daily sofosbuvir (400 mg) and daily daclatasvir (60 mg) +/- ribavirin 12-24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alfa-2a + Ribavirin</intervention_name>
    <arm_group_label>PEG/RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alfa-2a + Ribavirin + Boceprevir</intervention_name>
    <arm_group_label>PEG/RBV+BOC or TVR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alfa-2a + Ribavirin +Telaprevir</intervention_name>
    <arm_group_label>PEG/RBV+BOC or TVR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ledipasvir/Sofosbuvir</intervention_name>
    <arm_group_label>IF-DAAs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ombitasvir/paritaprevir/ritonavir+Dasabuvir</intervention_name>
    <arm_group_label>IF-DAAs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir+Sofosbuvir</intervention_name>
    <arm_group_label>IF-DAAs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simeprevir+Sofosbuvir</intervention_name>
    <arm_group_label>IF-DAAs</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic hepatitis C by genotype 1 and liver cirrhosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years.

          -  Signed informed consent.

          -  Chronic hepatitis C (anti-HCV antibodies and detectable HCV-RNA).

          -  Liver cirrhosis (transient elastography ≥ 14 kPa).

          -  Baseline upper gastrointestinal endoscopy to assess gastroesophageal varices

        Exclusion Criteria:

          -  Negative to provide signed informed consent.

          -  Negative to perform gastrointestinal endoscopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2016</study_first_submitted>
  <study_first_submitted_qc>April 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Parc de Salut Mar</investigator_affiliation>
    <investigator_full_name>José Antonio Carrion</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
    <mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

